Revolution Medicines Chief Development Officer Alan B. Sandler Exercises and Sells Shares Under Rule 10b5-1 Plan

Executive Summary

On October 1, 2026, Alan B. Sandler, Chief Development Officer of Revolution Medicines, Inc. ($RVMD), filed a Form 4 detailing derivative option exercises and subsequent open-market share sales executed on September 29, 2026. The transactions were conducted pursuant to a pre-arranged Rule 10b5-1 trading plan established on June 30, 2026.

Transaction Breakdown

1. Option Exercise (Code M):

   • Shares Acquired: 6,000 shares of Common Stock
   • Strike Price: $58.84 per share
   • Total Exercise Cost: $353,040.00

2. Open Market Sales (Code S):

   • Shares Sold: 6,000 shares sold in five weighted-average tranches:
     • 2,200 shares @ $200.8188 (range: $200.41 – $201.38)
     • 1,609 shares @ $201.7239 (range: $201.41 – $202.16)
     • 1,000 shares @ $202.8127 (range: $202.42 – $203.34)
     • 1,199 shares @ $203.9074 (range: $203.42 – $204.29)
     • 301 shares @ $204.7224 (range: $204.43 – $204.83)
   • Total Gross Sale Proceeds: $1,213,943.43
   • Blended Average Sale Price: ~$202.32 per share

Holdings and Context

Following these transactions, Dr. Sandler directly holds 52,559 shares of Common Stock (which includes 52,350 restricted stock units) and retains 161,300 stock options exercisable at $58.84 expiring on November 1, 2035.

Because the sale was a matched "cashless/same-day" exercise and sell pursuant to a Rule 10b5-1 trading plan adopted months prior, the filing represents standard executive compensation realization rather than a discretionary market-timing event.